A primer on brand-name prescription drug contracting
https://www.jmcp.org/doi/epdf/10.18553/jmcp.2024.24035

A primer on brand-name prescription drug contracting

The above is the title of a helpful primer from Kenney and Keast (2024). I summarize some key points below.

Provide an overview of the pharmacy contracts between stakeholders in the healthcare ecosystem.

How did the rise of health maintenance organizations (HMOs) impact pharmacy contracting?

The Health Maintenance Organization (HMO) Act of1973 spurred the growth of comprehensive health plans, such as Kaiser Foundation Health Plan, Group Health Cooperative of Puget Sound, and Health Insurance Plan of Greater New York. 3 It also required employers who offered insurance and had 25 or more employees to offer a federally quali?ed HMO if available in their market, which led to further expansion of HMO plans

Interesting points, but how are HMOs related to pharmacy contracts now?

Although pharmacy was not a standard part of bene?ts in the early HMO programs...some plans offered prescription drug coverage as an additional bene?t to attract members. HMOs that provided drug cover-age adopted formulary programs patterned after the hospital systems and created preferred drug lists with tiered copayments.

How are discounts incorporated in practice?

The table below summaries these calculations where Brand A is a high cost but high rebate product and Brand B is a low-cost but low rebate product.

The net price calculation starts with the contracted reimbursement amount between the PBM and the pharmacy, in which the reimbursement amount is typically a percentage of the wholesale acquisition cost (WAC). Next, any out-of-pocket cost (copay, coinsurance, or deductible) paid by the health plan member is subtracted. Finally, any rebates paid by the manufacturer to the PBM are subtracted to arrive at the net price paid by the PBM.
https://www.jmcp.org/doi/epdf/10.18553/jmcp.2024.24035

What types of contracts are there?

  • Purchase Discount Agreements. This agreement is a negotiated contracted for a drug that health plans pay when they purchase directly from the manufacturer as compared to through a PBM. If a wholesaler is used, the wholesalers use a "chargeback method" where the manufacturer authorizes the wholesaler to sell the product to the health plan at the contract price and the wholesaler simply charges back the manufacturer the difference between the WAC price and the contract along with an administrative fee.
  • Rebates. A rebate is a retroactive discount manufacturers provide to PBMs after a drug has been purchased and dispensed. In this process, the manufacturer pay a percentage of the drug price (the rebate) back to the PBM and the PBMs share all or a portion of rebates with health plans. Types of rebate agreements include an access agreement (rebate based on any formulary placement), a market share rebate (rebate based on market share or volume), or preferred formulary status agreement (rebate based on formulary tier).
  • Value-based contracts. The payment for the drug depends on the "value" of the product. Value could include specific patient outcomes, whether patients are adherent to the medication, CMS's Cell and Gene Therapy Models use value-based contracts.

You can read the full article including a discussion of Medicaid best price here.

Peggy Salvatore

Author, Songwriter, Singer

9 个月

Great to see Jim Kenney's work! Excellent summary of a complex process.

赞
回复

要查看或添加评论,请登录

Jason Shafrin的更多文章

  • Calculating Social Vulnerability Index by ZIP Code

    Calculating Social Vulnerability Index by ZIP Code

    A paper by Ng, Zhang and Kowal (2025) use the American Community Survey (ACS) data from 2016–2022 were used to…

    2 条评论
  • Value-Based Pricing for Drugs With Uncertain Clinical Benefits

    Value-Based Pricing for Drugs With Uncertain Clinical Benefits

    This is the title of a recent paper by Jiao et al. (2025).

    2 条评论
  • About face for RFK Jr. on MMR vaccine?

    About face for RFK Jr. on MMR vaccine?

    Last month, I noted that the decrease in vaccination rates has likely resulted in increased rates of measles in Texas…

    1 条评论
  • The value of knowing is not always positive

    The value of knowing is not always positive

    An interesting article by Ciancio et al. (2025) which examines the impact of learning one has HIV when no treatment is…

    1 条评论
  • More evidence that there are diminishing marginal returns to quality of life gains

    More evidence that there are diminishing marginal returns to quality of life gains

    Quality-adjusted life years (QALYs) are commonly used to evaluate the impact of new medical technologies on patient…

  • Quotation of the Day

    Quotation of the Day

    There is nothing so useless as doing efficiently that which should not be done at all. Peter Drucker

    1 条评论
  • What is Project IDEATE?

    What is Project IDEATE?

    How best can you design an outcomes based agreement (OBA)? What are the key factors to consider? Project IDEATE is a…

  • Can the NIH replace all private sector clinical R&D?

    Can the NIH replace all private sector clinical R&D?

    A paper by Proudman et al. (2024) finds that doing so would be extremely expensive.

    4 条评论
  • Vaccine choice = more measles infection

    Vaccine choice = more measles infection

    Texas is moving to allow for more freedom of choice with respect to receipt of vaccines. The Economist reports: Texas…

    3 条评论
  • Healthcare Economist named a top 100 Economics blog

    Healthcare Economist named a top 100 Economics blog

    In Feedspot's 2025 ranking of economics blogs, Healthcare Economist was once again ranked in the top 100 (#44). I was…

    16 条评论

社区洞察

其他会员也浏览了